Musculoskeletal Science and Translational Research Center, Department of Orthopedics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Int J Oncol. 2019 May;54(5):1704-1718. doi: 10.3892/ijo.2019.4737. Epub 2019 Feb 28.
Oncogenic drivers of osteosarcoma remain controversial due to the complexity of the genomic background of the disease. There are limited novel therapeutic options, and the survival rate of patients with osteosarcoma has not improved in decades. Genomic instability leads to complexity in various pathways, which is potentially revealed at the protein level. Therefore, the present study aimed to identify the mechanisms involved in the oncogenesis of osteosarcoma using proteomics and bioinformatics tools. As clinical specimens from patients are the most relevant disease‑related source, expression patterns of proteins in osteosarcoma tissues were compared with soft tissue callus from donors containing high numbers of osteoblastic cells. Two‑dimensional electrophoresis and liquid chromatography‑tandem mass spectrometry (LC‑MS/MS) successfully identified 33 differentially expressed proteins in the osteosarcoma tissues compared with the soft tissue callus. Among these proteins, 29 proteins were significantly upregulated in osteosarcoma. A functionally grouped network of the overexpressed proteins, that was created using the ClueGo and CluePedia applications, demonstrated that the unfolded protein response (UPR) pathway was activated mainly through the activating transcription factor 6 arm in osteosarcoma. The results of proteomics analysis were confirmed by elevated expression of UPR‑related chaperone proteins, including 78 kDa glucose‑related protein (GRP78), endoplasmin, calreticulin and prelamin‑A/C, in the patient‑derived primary cells and osteosarcoma cell lines. Furthermore, the expression of GRP78, a master regulator of the UPR, was enhanced in the osteosarcoma tissues of patients that were resistant to double regimen of doxorubicin and a platinum‑based drug. The findings of the present study suggest that targeting the UPR pathway may be promising for the treatment of osteosarcoma.
由于该病的基因组背景复杂,骨肉瘤的致癌驱动因素仍存在争议。目前治疗骨肉瘤的新方法有限,而且几十年来,骨肉瘤患者的生存率并没有提高。基因组不稳定性导致了多种途径的复杂性,这些复杂性可能在蛋白质水平上显现出来。因此,本研究旨在使用蛋白质组学和生物信息学工具来确定骨肉瘤发生的机制。由于患者的临床标本是与疾病最相关的来源,因此比较了骨肉瘤组织和含有大量成骨细胞的供体软组织骨痂中的蛋白质表达模式。二维电泳和液相色谱-串联质谱(LC-MS/MS)成功鉴定出骨肉瘤组织与软组织骨痂相比差异表达的 33 种蛋白质。在这些蛋白质中,有 29 种蛋白质在骨肉瘤中明显上调。使用 ClueGo 和 CluePedia 应用程序创建的过表达蛋白功能分组网络表明,未折叠蛋白反应(UPR)途径在骨肉瘤中主要通过激活转录因子 6 臂被激活。蛋白质组学分析的结果通过 UPR 相关伴侣蛋白的表达升高得到证实,包括 78 kDa 葡萄糖相关蛋白(GRP78)、内质网素、钙网蛋白和前层粘连蛋白 A/C,在患者来源的原代细胞和骨肉瘤细胞系中也是如此。此外,在对阿霉素和铂类药物双重方案耐药的患者骨肉瘤组织中,UPR 的主要调节因子 GRP78 的表达增强。本研究的结果表明,靶向 UPR 途径可能是治疗骨肉瘤的一种有前途的方法。